Pilatus Biosciences has reported promising preclinical results for PLT012, its lead metabolic checkpoint therapy, highlighting the potential of a novel approach to treating both liver disease and cancer. The findings reinforce the company’s strategy of targeting the intersection between metabolism and immune dysfunction, an area of growing interest for addressing complex chronic diseases.
PLT012 is a humanized monoclonal antibody that targets CD36, a key regulator of lipid uptake implicated in metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, and certain cancers. By blocking CD36-mediated lipid transport, the therapy aims to interrupt the chronic inflammation, tissue damage, and immune suppression that drive disease progression.
Across multiple preclinical models, PLT012 demonstrated the ability to reduce liver fat accumulation, inflammation, and fibrosis while improving markers of liver health. The therapy also showed broad immune-metabolic reprogramming, helping restore a more balanced immune environment. These findings suggest that targeting metabolic checkpoints could offer a new therapeutic strategy for patients with MASH and related liver disorders, where effective treatment options remain limited.
Beyond liver disease, PLT012 has demonstrated encouraging activity in oncology models, where it enhanced antitumor immune responses and showed potential to overcome resistance to existing immunotherapies. The program reflects Pilatus Biosciences’ vision of developing a platform of metabolic checkpoint therapies capable of addressing a range of diseases driven by immune and metabolic dysfunction.
These latest results further strengthen the clinical rationale for PLT012 and support its continued development as a first-in-class therapy with potential applications spanning metabolic disease, fibrosis, and cancer.
